Your browser doesn't support javascript.
loading
Pilot study of mobile phone technology in allergic rhinitis in European countries: the MASK-rhinitis study.
Bousquet, J; Caimmi, D P; Bedbrook, A; Bewick, M; Hellings, P W; Devillier, P; Arnavielhe, S; Bachert, C; Bergmann, K C; Canonica, G W; Chavannes, N H; Cruz, A A; Dahl, R; Demoly, P; De Vries, G; Mathieu-Dupas, E; Finkwagner, A; Fonseca, J; Guldemond, N; Haahtela, T; Hellqvist-Dahl, B; Just, J; Keil, T; Klimek, L; Kowalski, M L; Kuitunen, M; Kuna, P; Kvedariene, V; Laune, D; Pereira, A M; Carreiro-Martins, P; Melén, E; Morais-Almeida, M; Mullol, J; Muraro, A; Murray, R; Nogueira-Silva, L; Papadopoulos, N G; Passalacqua, G; Portejoie, F; Price, D; Ryan, D; Samolinski, B; Sheikh, A; Siroux, V; Spranger, O; Todo Bom, A; Tomazic, P V; Valero, A; Valovirta, E.
Afiliação
  • Bousquet J; MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France.
  • Caimmi DP; INSERM, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, U1168 Paris, and UVSQ, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Yvelines, France.
  • Bedbrook A; CHRU de Montpellier, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Sorbonne Universités, Paris, France.
  • Bewick M; Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France.
  • Hellings PW; MACVIA-LR, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France.
  • Devillier P; iQ4U Consultants Ltd, London, UK.
  • Arnavielhe S; Department of Microbiology and Immunology, Laboratory of Clinical Immunology, KU Leuven, Leuven, Belgium.
  • Bachert C; Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pôle des Maladies Respiratoires, Hôpital Foch, Suresnes Université Versailles Saint-Quentin, Versailles, France.
  • Bergmann KC; Kyomed, Montpellier, France.
  • Canonica GW; ENT Department, Upper Airways Research Laboratory, Ghent University Hospital, Ghent, Belgium.
  • Chavannes NH; Department of Dermatology and Allergy, Comprehensive Allergy-Centre-Charité, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Cruz AA; Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany.
  • Dahl R; Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy.
  • Demoly P; Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.
  • De Vries G; ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brasil.
  • Mathieu-Dupas E; GARD Executive Committee, Geneva, Switzerland.
  • Finkwagner A; ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brasil.
  • Fonseca J; GARD Executive Committee, Geneva, Switzerland.
  • Guldemond N; CHRU de Montpellier, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Sorbonne Universités, Paris, France.
  • Haahtela T; Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France.
  • Hellqvist-Dahl B; Peercode BV, Gerdermalsen, The Netherlands.
  • Just J; Kyomed, Montpellier, France.
  • Keil T; Global Allergy and Asthma Platform GAAPP, Vienna, Austria.
  • Klimek L; Center for Health Technology and Services Research - CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
  • Kowalski ML; Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal.
  • Kuitunen M; Institute of Health Policy and Management iBMG - Erasmus Universit, Rotterdam, The Netherlands.
  • Kuna P; Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.
  • Kvedariene V; Department of Respiratory Diseases, Odense University Hospital, Odense, Denmark.
  • Laune D; Allergology Department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Sorbonne Universités, Paris, France.
  • Pereira AM; Institute of Social Medicine, Epidemiology and Health Economics, Charité -Universitätsmedizin Berlin, Berlin, Germany.
  • Carreiro-Martins P; Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany.
  • Melén E; Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Morais-Almeida M; Department of Immunology, Rheumatology and Allergy, Healthy Ageing Reseach Centre (HARC), Medical University of Lodz, Lodz, Poland.
  • Mullol J; Children's Hospital, University of Helsinki and University Hospital of Helsinki, Helsinki, Finland.
  • Muraro A; Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
  • Murray R; Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania.
  • Nogueira-Silva L; Kyomed, Montpellier, France.
  • Papadopoulos NG; Center for Health Technology and Services Research - CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
  • Passalacqua G; Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal.
  • Portejoie F; CEDOC, Respiratory Research Group, Nova Medical School, Campo dos Martires da Patria, Lisbon, Portugal.
  • Price D; Serviço de Imunoalergologia, Hospital de Dona Estefânia, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal.
  • Ryan D; Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden.
  • Samolinski B; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Sheikh A; Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisboa, Portugal.
  • Siroux V; ENT Department, Hospital Clinic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Spranger O; Department of Women and Child Health, Food Allergy Referral Centre Veneto Region, Padua General University Hospital, Padua, Italy.
  • Todo Bom A; Medical Communications Consultant, MedScript Ltd, Dundalk, Co Louth, Ireland.
  • Tomazic PV; Center for Health Technology and Services Research - CINTESIS, Porto, Portugal.
  • Valero A; Department of Internal Medicine, Centro Hospitalar Sao Joao, Porto, Portugal.
  • Valovirta E; Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.
Allergy ; 72(6): 857-865, 2017 Jun.
Article em En | MEDLINE | ID: mdl-28072463
ABSTRACT

BACKGROUND:

The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms).

AIMS:

To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions.

METHODS:

The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms.

RESULTS:

By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction.

CONCLUSIONS:

This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Telefone Celular / Rinite Alérgica Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Allergy Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Telefone Celular / Rinite Alérgica Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Allergy Ano de publicação: 2017 Tipo de documento: Article País de afiliação: França